Seeking Alpha

Alkermes Inc. (ALKS)

()

News & PR
Market Currents

Buzz
Twitter: ALKS

Business Intelligence
Transcripts
Events
Key Developments

Analysis - Latest Articles by most recent | most commented

Diabetes Care: Global Investing Opportunities

Nov 22 • Mike Havrilla • 4 Comments
Tuesday's Big Gainers on Heavy Volume

Nov 18 • Marco Hickey • Comment!
BioMed News Bytes: Cytori, Poniard, Alkermes, Spherix, CRXX, HGSI

Nov 17 • Mike Havrilla • 2 Comments
Wednesday Options Recap

Nov 11 • Frederic Ruffy • 2 Comments
Three Recent Biotech Activist Wins by Carl Icahn

Aug 31 • Michael Becker • 4 Comments
Wall Street Breakfast: Must-Know News

Aug 7 • SA Editor Rachael Granby • 18 Comments
FDA Calendar: 2H09 Binary Event Trades

Jul 27 • Mike Havrilla • 3 Comments
Smaller Pharma Wins the 'Most Valuable' Race

Jul 1 • EP Vantage • 1 Comment
74 Solid, Growing Companies in a Recession

Jun 30 • Davy Bui • 1 Comment
30 Possible Pandemic Profit Plays: Bullish Biotech and Drug Stocks to Watch

Jun 28 • Marco Hickey • 1 Comment
Aradigm: Hard to Value, But Significant Upside

Jun 19 • Zacks.com • 1 Comment
Biotech Opportunities: Look for Decent Pipeline, Big Pharma Partnerships

Jun 2 • Zacks.com • 15 Comments
Alkermes Outlook Remains Bleak

May 26 • Zacks.com • Comment!
Wall Street Breakfast: Must-Know News

May 22 • SA Editor Eli Hoffmann • 13 Comments
FDA Calendar Updates: Acusphere, AspenBio, Alkermes

May 19 • Mike Havrilla • 3 Comments
Who Will Win the Amylin Battle?

May 7 • Mike Huckman • 1 Comment
Early Filing for Byetta: Will It Become a Blockbuster?

May 6 • Mike Huckman • 1 Comment
FDA Calendar Updates: Amylin, Alkermes, Eli Lilly, Cell Therapeutics

May 6 • Mike Havrilla • 3 Comments
FDA, Clinical Trial Calendar Updates: Acorda, Alkermes, GTx

Apr 23 • Mike Havrilla • Comment!
15 'Bathwater Babies' and 20 'Dogs with Fleas' for the Week

Apr 5 • J Clinton Hill • 2 Comments
Which Diabetes Drugs Will Win Out?

Apr 2 • Mike Huckman • 3 Comments
Merck's Jumpin' Januvia Gets a Reprieve

Mar 8 • Mike Huckman • Comment!
Monthly Big 5: Stocks Worth Watching

Feb 4 • GT McDuffy • 2 Comments
Updated FDA Calendar: Cypress Bioscience Looks Like a Buy

Dec 12, 2008 • Mike Havrilla • 1 Comment
Eli Lilly's CEO: 'Ludicrous' Stock Price

Dec 12, 2008 • Mike Huckman • 2 Comments
Nine Pharma Predictions for 2009

Dec 2, 2008 • Mike Huckman • 2 Comments
Wall Street Breakfast: Must-Know News

Nov 5, 2008 • SA Editor Eli Hoffmann • 20 Comments
Recessionary Equity Strategies: Still Going for Growth

Nov 5, 2008 • Marc Gerstein • 1 Comment
Tuesday Options Update: ADM, KGC, AMLN, ALKS, SOLF, HLF & EXPD

Nov 4, 2008 • Andrew Wilkinson • Comment!
Why I'm Buying Amylin Now

Aug 20, 2008 • TraderMark • 10 Comments
So Much for the Summer Doldrums with Drugmakers

Aug 3, 2008 • Mike Huckman • Comment!
BioMarin, Myriad, and Regeneron Show a Quiet Strength

Jun 26, 2008 • Zacks.com • Comment!
Is Lilly and Amylin's Byetta Better?

Jun 11, 2008 • Mike Huckman • 2 Comments
Analyst Notes: Lilly Gets A Lift, Pfizer Goes Pfft

Jun 5, 2008 • Mike Huckman • Comment!
Biotech Sector Continues to Outperform

May 29, 2008 • Zacks.com • Comment!
Wall Street Breakfast: Must-Know News

May 23, 2008 • SA Editor Eli Hoffmann • 7 Comments
Generex Biotechnology: Oral-lyn Buccal Insulin Takes Center Stage

Apr 10, 2008 • R.J Steffens • 13 Comments
Inhaled Insulin: Eli Lilly On Its 'Last Breath'?

Mar 9, 2008 • Mike Huckman • Comment!
Alkermes Should Profit From Lilly's Delayed Drug

Feb 29, 2008 • Notable Calls • 3 Comments
Alkermes, Lilly, Mannkind: Inhaled Insulin Just Got Interesting

Jan 22, 2008 • Michael Shulman • 5 Comments
Eat It, Breathe It, Soak in It? Drug Administration Gets Tricky

Jan 20, 2008 • Derek Lowe • 1 Comment

Alkermes Inc. (ALKS)

Analysis - Latest Articles by most recent | most commented

The Seeking Alpha 100

Fastest Climbers

Top Commenters

Top Instabloggers

Top StockTalkers